INFIMEDIC: sector benchmark
Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.
INFIMEDIC
Summary
INFIMEDIC does better than half of its sector on 4 of the 7 ratios compared.
- Solvencybetter than 91%
- Current ratiobetter than 89%
- Debt to equitybetter than 88%
- Return on equitybetter than 14%
- Return on assetsbetter than 22%
- Interest coveragebetter than 30%
Solvency and debt
Solvency is above 91% of 19,634 sector peers: in the most favourable quarter.
Position against the sector stable since 2021.
Debt to equity is below 88% of 19,174 sector peers: in the most favourable quarter.
Position against the sector stable since 2021.
Interest coverage is below 70% of 18,692 sector peers: less favourable than the median.
Position against the sector weakening since 2021.
Liquidity
The current ratio is above 89% of 19,341 sector peers: in the most favourable quarter.
Position against the sector stable since 2021.
The working-capital ratio is above 75% of 19,608 sector peers: in the most favourable quarter.
Position against the sector improving since 2021.
Profitability
Return on equity is below 86% of 17,899 sector peers: in the least favourable quarter.
Position against the sector weakening since 2021.
Return on assets is below 78% of 19,601 sector peers: in the least favourable quarter.
Position against the sector weakening since 2021.
Not computable
Long-term debt ratio, Net margin, EBITDA margin, Gross margin, Days sales outstanding, Days payable outstanding, Days inventory. This company files the abbreviated or micro schema, in which turnover and purchases are optional; margins and credit terms therefore cannot be taken from its figures.
Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 28 September 2026 via checked.be.